Summary:
In patients with diabetic nephropathy (DN), a structured nutritional intervention combined with dapagliflozin significantly enhanced glycaemic control, renal function, nutritional status, and quality of life compared to dapagliflozin alone (10 mg/day) or conventional care, though it was associated with no significant difference in adverse event rates.
| PICO | Description |
|---|---|
| Population | Adults (n=108) diagnosed with diabetic nephropathy (DN). |
| Intervention | Dapagliflozin 10 mg/day combined with a structured Mediterranean diet and oral nutritional supplements. |
| Comparison | Dapagliflozin 10 mg/day alone or conventional care without dapagliflozin or nutritional intervention. |
| Outcome | The group receiving nutritional intervention plus dapagliflozin showed superior improvements in HbA1c (-1.5% vs -0.9%), UACR reduction (-48% vs -35%), and nutritional markers such as albumin and ferritin. Quality of life scores (SF-36) were significantly higher, and inflammatory markers were reduced more markedly than in the comparison groups. No significant differences in adverse events were reported. |
Clinical Context
Diabetic nephropathy management has been transformed by SGLT2 inhibitors like dapagliflozin, which provide renal protection independent of glucose lowering through mechanisms including reduced intraglomerular pressure, decreased albuminuria, and anti-inflammatory effects. However, patients with diabetic kidney disease frequently experience malnutrition due to uremia-related anorexia, dietary protein restrictions, and chronic inflammation. This protein-energy wasting syndrome accelerates disease progression and worsens outcomes. The Mediterranean dietary pattern has demonstrated cardiovascular and metabolic benefits in diabetes, while oral nutritional supplements can address micronutrient deficiencies and protein insufficiency common in chronic kidney disease. Whether combining structured nutritional support with SGLT2 inhibitor therapy produces additive or synergistic benefits beyond pharmacotherapy alone represents an important clinical question. This three-arm trial evaluated whether a comprehensive nutritional intervention enhances the established benefits of dapagliflozin in diabetic nephropathy.
Clinical Pearls
- The combination of nutritional intervention plus dapagliflozin produced 67% greater HbA1c reduction (-1.5%) compared to dapagliflozin alone (-0.9%), suggesting synergistic glycemic benefits.
- Urinary albumin-to-creatinine ratio decreased 48% with combination therapy versus 35% with dapagliflozin alone, indicating enhanced renal protection from the nutritional component.
- Nutritional markers including serum albumin and ferritin improved significantly with the combined approach, addressing the protein-energy wasting common in diabetic nephropathy.
- Quality of life measured by SF-36 showed significantly higher scores with combination therapy, reflecting the comprehensive benefits of addressing both pharmacological and nutritional needs.
Practical Application
Clinicians managing diabetic nephropathy should integrate structured nutritional counseling and supplementation alongside SGLT2 inhibitor therapy rather than relying on medication alone. Referral to registered dietitians for Mediterranean diet education and assessment of protein-energy status should be standard practice. Oral nutritional supplements may be indicated for patients with evidence of malnutrition, hypoalbuminemia, or difficulty maintaining adequate dietary intake. The combination approach addresses multiple pathophysiological mechanisms simultaneously: dapagliflozin provides hemodynamic and metabolic kidney protection while nutritional optimization combats inflammation, improves protein status, and supports overall metabolic health. This multimodal approach aligns with holistic chronic disease management principles that extend beyond single-medication interventions.
Broader Evidence Context
These findings reinforce the importance of lifestyle intervention alongside pharmacotherapy in diabetes management. The Mediterranean diet has established benefits for cardiovascular risk reduction and glycemic control, with mechanisms including anti-inflammatory effects, improved lipid profiles, and favorable impacts on gut microbiome composition. SGLT2 inhibitors have demonstrated renal and cardiovascular benefits across multiple large outcomes trials including CREDENCE and DAPA-CKD. This study suggests these evidence-based interventions may be complementary rather than substitutive, providing rationale for comprehensive treatment approaches. The results align with guideline recommendations emphasizing both pharmacological and lifestyle interventions in diabetic kidney disease management.
Study Limitations
- The relatively small sample size of 108 participants limits statistical power for subgroup analyses and detection of less common adverse events.
- Study duration was not specified in the summary, leaving uncertainty about long-term sustainability of benefits.
- The nutritional intervention combined dietary counseling with supplementation, making it impossible to attribute effects to individual components.
- Adherence to dietary recommendations was not objectively measured beyond self-report.
- The study population and setting may limit generalizability to other healthcare contexts and patient demographics.
Bottom Line
Combining structured Mediterranean diet intervention and nutritional supplementation with dapagliflozin therapy produces greater improvements in glycemic control, renal function, nutritional status, and quality of life compared to dapagliflozin alone in diabetic nephropathy. Clinicians should implement comprehensive nutritional support alongside SGLT2 inhibitor therapy for optimal outcomes.
Source: Liu, Yifan, et al. “Adjunctive nutritional intervention improves glycaemia and quality of life in dapagliflozin-treated diabetic patients.” Pakistan Journal of Pharmaceutical Sciences. Read article here.
